Among women in Europe, ovarian cancer is the fifth most common cancer and the sixth leading cause of cancer death.
The five-year survival rate for ovarian cancer in Europe is 38%.
In 2012, there were nearly 65,000 new cases diagnosed and around 42,700 deaths.
As there is no cure for relapsed ovarian cancer, the primary aim of treatment is to slow progression of the disease for as long as possible and improve or maintain the patient’s quality of life.

Lynparza ( Olaparib ) is a first-in-class poly ADP-ribose polymerase ( PARP ) inhibitor and the first targeted treatment to potentially exploit tumour DDR-pathway dependencies to preferentially kill cancer cells.
Specifically, in vitro studies have shown that Olaparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes, resulting in DNA damage and cancer-cell death.

SOLO-2

SOLO-2 was a randomised, double-blinded, multicentre trial designed to determine the efficacy of Olaparib tablets compared to placebo as maintenance monotherapy in patients with Platinum-sensitive relapsed or recurrent germline BRCA-mutated ovarian, fallopian tube and primary peritoneal cancer.
The trial, conducted in collaboration with the European Network for Gynaecological Oncological Trial Groups and Groupe d’Investigateurs National pour l’Etude des Cancers de l’Ovaire et du sein, randomised 295 patients with documented germline BRCA1 or BRCA2 mutations who had received at least two prior lines of Platinum-based chemotherapy and were in complete or partial response.
Eligible patients were randomised to receive 300mg Lynparza tablets twice daily or placebo tablets twice daily.

Study 19

Study 19 was a randomised, double-blinded, placebo-controlled, multi-centre trial, which evaluated the efficacy and safety of Olaparib compared with placebo in relapsed, high-grade serous ovarian cancer patients.
The trial randomised 265 patients regardless of BRCA mutation status and who had completed at least two courses of Platinum-based chemotherapy and their most recent treatment regimen.
Eligible patients were randomised to receive Olaparib maintenance monotherapy at a dose of 400mg per day or matching placebo. ( Xagena_2018 )

Source: AstraZeneca, 2018

Xagena_Medicina_2018